Introduction
The reverse transcriptase (RT) of HIV-1 is a multifunctional enzyme that catalyzes the conversion of viral genomic RNA into double-stranded proviral DNA. RT is an important target for antiviral chemotherapy because it is essential for viral replication. Two classes of inhibitors are currently being used in the management of HIV infection. Non-nucleoside RT inhibitors (NNRTIs) bind directly to a hydrophobic pocket adjacent to the polymerase active site of RT. Nucleoside RT inhibitors (NRTIs) such as zidovudine (AZT) and lamivudine (3TC), which are being widely used in the treatment of HIV infection, act by competing with natural substrates at the HIV RT active site, leading to incorporation and termination of the DNA chain. Unlike most cellular DNA polymerases, RT exhibits lower fidelity and processivity than cellular DNA polymerases and lacks a 3′-to 5′-proofreading activity, resulting in a high mutation rate and drug resistance (Preston et al., 1988; Roberts et al., 1988; Huber et al., 1989; Kellam et al., 1992; Yu & Goodman, 1992) . Anti-HIV therapy is limited because of a number of factors, including development of viral drug resistance and significant host toxicity often observed following long-term exposure to antiviral drugs (Table 1) (Larder & Kemp, 1989; Gao et al., 1992) . Consequently, efforts continue to identify potent antiviral agents effective against drug resistant virus. (-)-β-DDioxolane guanine (DXG) and its prodrug, 2,6-diaminopurine (DAPD), have been reported to be potent inhibitors of HIV-1 (Kim et al., 1993; Siddiqui et al., 1993; Furman et al., 2001) . When recombinant or clinical variants of HIV-1 were used to assess the efficacy of this purine nucleoside analogue against drug-resistant HIV-1, it was observed that AZT-resistant and 3TC-resistant virus Molecular mechanism of DAPD/DXG against zidovudine-and lamivudine-drug resistant mutants: a molecular modelling approach (Gu et al., 1999; Furman et al., 2001) . These findings have particular importance because even though these two NRTIs (AZT and 3TC) are the most widely used combination therapy regimen, RT can become multidrug resistant under prolonged combination therapy (Shirasaka et al., 1995; Carpenter et al., 1997; Larder & Stammers, 1999) . Therefore, the investigation of the characteristic binding patterns of DXG to the drugresistant RTs might help us understand drug resistance mechanism, and, eventually, design more effective NRTIs.
In the absence of structural data for NRTI-resistant RTs, various mechanisms have been proposed to explain the action of such mutations. These include selective alterations in NRTI binding and/or incorporation, template/primer (T/P) repositioning and NTP mediated as well as phosphorolytic removal of an incorporated chainterminating NRTI residue from the 3′-end of the nascent viral DNA (Arts & Wainberg, 1996; Sluis-Cremer et al., 2000) . However, even though the phosphorolytic removal of AZT gains more support from other investigations (Sluis-Cremer et al., 2000) , there has not been clear explanation about the detailed mechanism of the resistance at a molecular level.
Based on the X-ray structure of the covalently trapped catalytic complex of RT (Huang et al., 1998) , Huang et al. have found that the point mutations sufficient for resistance (K65R, K70R, L74V, Q151M, M184I/V and T215Y/F) are all in the neighbourhood of the incoming nucleotide. Therefore the primary mutations are likely to affect directly the position, stability, or reactivity of the bound analogue itself or additionally the templating base or primer terminus. In other words, there might be significant differences in binding patterns and binding energies of nucleoside tirphosphates (NRTIs as well as natural substrates) to wild-type (WT) with respect to the mutant enzymes. This idea prompted us to correlate the binding affinities of nucleoside analogues to the WT and mutant RT with the resistance conferred by mutations. A direct comparison of binding affinities of NRTIs to RT with their biological activity (EC 50 ) has not been thought to be possible because the efficiency of inhibition of HIV-1 replication by NRTIs is dependent on many factors, including cellular uptake, phosphorylation by kinases and the efficiency of an analogue binding to RT, and subsequent incorporation into the elongating viral DNA (Hao et al., 1988) . However, assuming that the mutation at RT does not affect any other events of NRTIs but its own structure and functions, it becomes possible to correlate the biological activity (EC 50 ) with the difference in the binding affinities of the NRTIs to mutant RT with respect to those to the WT RT. Furthermore, if we compare the binding energies of the NRTIs with those of the corresponding natural substrates, we have more chance to correlate the antiviral activity (EC 50 ) with the events at the binding to the RT. For this purpose, we conducted molecular modelling studies on WT RT as well as RT mutated at specific residues. Three structurally different nucleotide inhibitors, AZT-TP, 3TC-TP and DXG-TP (Figure 1 ), were chosen due to their distinct structural features as well as their unique drug resistance profiles. The NRTI triphosphates were docked into the WT and mutant (M41L/D67N/K70R/T215Y, M184V, K65R, L74V and K65R/Q151M) RT active sites, and then the resulting structures were minimized. The binding affinities of the examined structures toward HIV-1 RT were estimated by means of the binding energy differences (relative binding energy, E rel , Tables 2-4) between the NRTI-TP (DXG-TP, AZT-TP or 3TC-TP)-RT complex and the corresponding natural substrate, 2′-deoxynucleoside triphosphates (dNTPs: dGTP, TTP or dCTP)-RT complex in the energy-minimized states. The relative binding energies of DXG-TP, AZT-TP and 3TC-TP (E rel , Tables 2-4) were correlated with the anti-HIV activity of the nucleoside inhibitors, and the minimized structures of both WT and mutant enzymes bound to each Y Chong et al. ddC (4-10), ddI (4-10), 3TC (17), abacavir (3), DXG (5.6) L74V ddI (5-10), ddC (5-10), abacavir (4), DXG (3.5) M184I/V 3TC (>1000), ddC (2-5), abacavir (2-5) V75T ddC, ddI, d4T (7) Q151M
Multidrug resistance, appears in patients with resistance to multiple ddN K65R/Q151M DXG (>20) *Schinazi et al. (2000) . AZT, zidovudine; ddC, zalcitabine; 3TC, lamivudine; ddI, indinavir, d4T, stavudine.
inhibitor were analysed to obtain the molecular mechanism of drug resistance conferred by mutations in RT.
Materials and methods
All molecular modeling of the enzyme-substrate complexes was carried out using SYBYL 6.6 (Tripos Inc. St Louis, Mo., USA).
HIV-1 RT structure (PDB entry 1rtd)
HIV-1 RT is a heterodimer comprising subunits of 66 and 51 kDa (p66 and p51). The overall shape of the p66 subunit has been likened to that of a right hand, with the major subdomains of the polymerase domain of p66 appropriately termed fingers, palm and thumb. The DNA polymerase catalytic aspartate residues (Asp110, Asp185, and Asp186) are in the palm subdomain, and the mutations associated with NRTI resistance occur primarily in the fingers and the palm subdomains of RT. Comparison of the structures of free RT with that of the RT-T/P binary complex shows that the interaction of RT with T/P duplex induces a conformational rotation of the p66 thumb subdomain (Ding et al., 1998 , Jacobo-Molina et al., 1993 . Comparison of the structures of the RT-T/P binary complex with the RT*-T/P-dNTP (RT*; catalytically competent RT) ternary complex reveals that dNTP binding induces further conformational changes in RT (Huang et al., 1998) . In particular, part of the fingers subdomain rotate inwards toward the palm subdomain and the polymerase active site, effectively clamping the dNTP into the active site region. Therefore in order for the enzyme-ligand complex to be catalytically active, there must be some conformational changes in RT leading to a tight binding of the substrate. The sugar 3′-OH of the dNTP projects into a small pocket formed by the side chains of D113, A114, Y115, F116 and Q151. Interestingly, the 3′-OH of the nucleotide forms hydrogen bonds with the backbone -NH of Y115 and triphosphate moiety of the dNTPs. However, since the NRTIs used in this study lack 3′-OH, the adjacent enzyme residues such as Arg65, Lys70 and Arg72 should be involved in stabilizing the bound nucleoside.
Model enzyme site
The enzyme site of the enzyme-ligand complex was constructed based on the X-ray structure of the covalently trapped catalytic complex of HIV-1 RT with TTP and primer-template duplex (PDB entry 1rtd) (Huang et al., 1998) . Given the large size of the HIV-1 RT, calculations of the entire protein-ligand complex were not practical. Therefore, a model of the NRTI binding site was constructed, which consisted of residues between Lys1 and Pro243 in the p66 subunit. Hydrogen atoms were added, and the clipped residues (Lys1 and Pro243) were capped with acetyl groups. The template-primer duplex had to be truncated as well. Interestingly, 5:2 (template:primer, ratio of bases) duplex was not stable enough, presumably because of the insufficient base stacking interaction to maintain the duplex structure. Thus, a 7:4 (template:primer) duplex, which was shown to be stable enough to give a reliable result was used for the modelling studies (Lee & Chu, 2001 ). The missing 3′-OH group in G22 [the 3′-end (n th ) nucleotide in the primer strand] in the original X-ray coordinates (1rtd) (Huang et al., 1998) was added, so that it could properly co-ordinate the adjacent Mg atom. Three clipped residues in template and primer strands [G3, C19(template)/ G9(primer)] were capped with methyl groups.
Nucleoside reverse transcriptase inhibitors
The initial Cartesian coordinates for each inhibitor were generated based on the X-ray co-ordinates (AZT) (van Roey et al., 1988) or conformational analysis (3TC) (Lee & Chu, 2001 ). The X-ray coordinates of D-dioxolane cytosine (Kim et al., 1992) were used as a template for construction of DXG structure, whose heterocyclic base moiety, cytosine, was modified to guanine before docking into the enzyme. The heterocyclic moiety of n+1 th nucleotide in template overhang was modified to the base complementary to the incoming NRTIs. Thus, in 3TC-TP and DXG-TP modelling, the adenine moiety, which was in the original X-ray structure (1rtd) (Huang et al., 1998) , was modified to guanine and cytosine, respectively. The enzyme site and the inhibitor were merged to form a catalytic complex, and then the NRTI triphosphate was situated in such an orientation that it could be paired with its complementary base in the template strand by adjusting the torsional angles to those found in the X-ray structure (Huang et al., 1998) 
Method
Gästeiger-Hückel charge (Purcell & Singer, 1967; Gästeiger & Marsili, 1980) was given to the enzyme-ligand complex with formal charges (+2) to two Mg atoms in the active site. Then, Kollman-All-Atom charges (Halley et al., 1976; Blaney et al., 1982; Wipff et al., 1983) were loaded to enzyme site from the biopolymer option in SYBYL 6.6 (Tripos Inc. St Louis, Mo., USA). The mutated enzyme sites (M41L/D67N/K70R/T215Y, M184V, K65R, L74V and K65R/Q151M) were constructed by modifying the WT enzyme site by point mutation or a combination of the point mutations of the amino acid residues. In order to eliminate local strains resulting from merging inhibitors and/or point mutations, residues inside 6 Å from the merged inhibitors and mutated residues were annealed ('annealing' means minimization of a subset of a macromolecule to perform energy refinement (strain relaxation) on local regions of large structures. Detailed information can be found in the 'Biopolymer modelling manual', pp54-60, Tripos Bookshelf, version 6.6) until energy change from one iteration to the next was less than 0.05 kcal/mol [hot region: 6 Å, interesting region: 12 Å, Kollman-All-Atom Force Field (Weiner et al., 1986) , Kollman-All-Atom charge (Halley et al., 1976; Blaney et al., 1982; Wipff et al., 1983) ] for enzyme and Gästeiger-Hückel charge (Purcell & Singer, 1967; Gästeiger & Marsili, 1980) for duplex. The annealed enzyme-inhibitor complexes were minimized by using Kollman-All-Atom Force Field (Weiner et al., 1986) until iteration number reached 5000 or the energy change from one iteration to the next was less than 0.05 kcal/mol. The binding affinities of the examined structures toward HIV-1 RT were estimated by means of the relative binding energy (E rel , Tables 2-4) between the inhibitor triphosphate (DXG-TP, AZT-TP or 3TC-TP)-RT complex and the corresponding natural substrate (dGTP, TTP or dCTP)-RT complex in the energy-minimized states.
Results

Calculation of relative binding energy
The binding affinities were estimated by means of the binding energy differences (relative binding energy, E rel )
between the NRTI triphosphate (DXG-TP, AZT-TP or 3TC-TP)-RT complex and the corresponding natural substrate, 2′-deoxynucleoside triphosphates (dNTPs: dGTP, TTP or dCTP)-RT complex. The binding energy (E b ) of each nucleoside-TP was calculated using equation 1.
Where, E b =binding energy of the NRTI-TP or dNTP to RT; E(enzyme)=energy of RT-DNA duplex complex; E(ligand)=energy of NRTI triphosphate or dNTP; E(enzyme-ligand complex)=energy of RT-DNA duplex-NRTI triphosphate ternary complex or RT-DNA duplexdNTP ternary complex. The relative binding energy (E rel ) of the NRTI triphsophate was calculated by the difference of the binding energy between NRTI triphosphate and the corresponding dNTP (equation 2).
Therefore, a favourable binding affinity would be represented by a large positive E rel , and a poor binding NRTI-TP would have a small or negative E rel .
The computational analyses indicated that the antiviral activity of the nucleoside RT inhibitors can be influenced by the binding affinity of their TP to RT. In WT enzyme sites, DXG-TP, AZT-TP and 3TC-TP showed favourable binding affinities toward RT (Tables  2-4 ). The calculated relative binding energy (E rel ) for AZT to the AZT-resistant mutant (WT: 146.4 and M41L/D67N/K70R/T215Y: 73.4 kcal/mol) showed a good correlation with the drug resistance ( Table 2) . 3TC also showed a significant decrease in E rel (Table 3) toward the 3TC-resistant mutant (WT: 76.4 and M184V: -28.8 kcal/mol). Interestingly, DXG showed a linear correlation of E rel with drug resistance. Both AZT-and 3TC-resistant mutant strains (M41L/D67N/K70R/T215Y: 8.0 and M184V: 5.7 kcal/mol) maintained favourable affinities to DXG (Tables 2 and 3 ), but the mutants that confer resistance to DXG showed a significantly decreased E rel (K65R: -37.1, L74V: 0.2 and K65R/Q151M: -44.4 kcal/mol, Table 4 ).
Analysis of the minimized structure of reverse transcriptase-zidovudine-triphosphate complex
The most widely used clinical therapeutic against the HIV-1 is the nucleoside analogue 3′-azido-3′-deoxythymidine (AZT), and it is the most potent nucleoside in vitro (EC 50 0.002 µM in peripheral blood mononuclear cells) among the NRTI anti-HIV drugs approved so far (Eriksson et al., 1988) . However, prolonged clinical use of AZT monotherapy invariably results in the appearance of HIV-1 resistant to the drug (Table 1 ). The calculated relative binding energy (E rel ) of AZT-TP toward RT showed that the E rel could be correlated with the antiviral activity of AZT for WT RT and quadruple mutant resistant to AZT (M41L, D67N, K70R, T215Y ) ( Table 2) .
Wild-type-reverse transcriptase-zidovudinetriphosphate complex
On the basis of their crystal structure of WT RT/DNA/dNTP, Huang et al. (1998) have suggested that the '3′-OH pocket', lined by the side chains of Asp113, Tyr115, Phe116 and Gln151, and the peptide backbone between 113 and 115 can probably accommodate two or three water molecules in addition to the 3′-OH, and it clearly has room for the azido group of AZT-TP. Many spectroscopic and kinetic studies showed that TTP and AZT-TP have the same binding site as well as the same binding conformation when they are bound to RT, which supports the significance of the role of the pocket for AZT-TP binding (Matthes et al., 1987; Furman et al., 1991 Furman et al., , 1992 Painter et al., 1991 Painter et al., , 1993 West et al., 1992) . Recent pre-steady-state kinetic analysis of WT RT (Kerr & Anderson, 1997) showed that there is about twofold difference in binding affinity (K d ) between TTP and AZT-TP, which can be correlated with our calculated E rel ( Table  2 ). The comparison of the binding modes showed that there are two major differences. Different ring conformation between the natural substrate (TTP) and AZT-TP allows an inward rotation of ε-amino group of Arg72 to the binding site (Figure 2a) to form a stable binding interaction between the enzyme and the triphosphate moiety of AZT-TP. The bulky azido group of AZT-TP, however, can be accommodated in the binding pocket without any steric conflict with neighbouring enzyme residues and form hydrogen bonds with Tyr115 and Phe116 backbone -NH groups (Figure 2a) . A combination of these two factors induces conformational changes in tertiary structure of the RT to form a tight complex by closing the gap between the fingers and palm domains (Figure 2b ), which may be responsible for the difference in binding affinity as well as the potent anti-HIV activity of AZT-TP.
The quadruple mutant (M41L/D67N/K70R/T215Y) reverse transcriptasezidovudine-triphosphate complex AZT resistance correlates with multiple mutations in RT, including M41L, D67N, K70R, L210W, T215Y/F and Q219K (Tables 1 and 2 ) (Larder & Kemp 1989; Kellam et al., 1992; Harrigan et al., 1996; Hooker et al., 1996) . The extent of AZT resistance is related to the combination of mutations present. In general, two or more of these mutations in RT are normally needed to exhibit high-level AZT resistance (Lacey et al., 1992; Moyle 1995) . Examination of WT RT/DNA/dNTP ternary complex (Huang et al., 1998) shows that AZTresistance mutations all cluster around the dNTP binding pocket, suggesting a direct influence on AZT binding. However, detailed kinetic analyses were unable to detect significant differences between WT and AZT-resistant RT for the incorporation of AZT-TP into the DNA chain (Carroll et al., 1994; Kerr & Anderson, 1997;  Krebs et al., 1997) . Several groups have proposed that AZT resistance can involve the phosphorolytic removal of the chain-terminating AZT from the 3′-terminus of the primer after it has been incorporated into viral DNA, and this mechanism has been supported by other investigations (Meyer et al., 1998; Arion et al., 1998; Arion & Parniak, 1999; Meyer et al., 1999; Boyer et al., 2001) . Recently, Boyer et al. (2001) used both structural and biochemical data to develop a model, which showed that ATP is most likely pyrophosphate donor in in vivo excision reaction and AZT resistant mutations serve to increase the affinity of RT for ATP so that, at physiological ATP concentrations, excision is reasonably efficient (Boyer et al., 2001) . Their modelling study showed that the specificity of the excision reaction for an AZT-terminated primer is due to the structure of the region around the HIV-1 RT polymerase active site and its interaction with the azido group of AZT. Steric constraints involving the azido group cause the end of an AZT 5′-monophosphate-terminated primer to preferentially reside at the nucleotide binding site, which favours excision (Boyer et al., 2001) . However, our result shows that the mutations still interfere with the ability of HIV-1 RT to incorporate AZT-TP. The calculated binding energy of AZT-TP toward the quadruple mutant (M41L/ D67N/ K70R/ T215Y) RT shows a sharp drop in comparison with the WT enzyme ( Table 2) . No significant change in either the binding conformation of AZT-TP or the conformations of pocket residues (Asp113, Tyr115, Phe116 and Gln151) could be found, but a close comparison with TTP binding to this multiple mutant enzyme revealed an interesting change in the conformation of the enzyme-ligand complex mediated by the interaction between the triphosphate moiety of AZT-TP and the Arg70 residue of RT. The lack of 3′-OH in AZT-TP as well as the mutation K70R results in a shift of the entire triphosphate moiety outward from the binding site (0.8 Å). As a result, the Arg70, which interacts with the γ phosphate, shifts significantly (∼3 Å) out of the binding pocket in order to maintain its hydrogen bonding to γ phosphate (Figure 2c ). This movement of Arg70 exerts significant effects to the three dimensional structure of the enzyme-ligand (AZT-TP) complex (Figure 2d ): the hydrogen bond between Arg70 and Asp113 is not effective any more and the movement of Arg70 unfolds the palm domain resulting in a loose and ineffective binding mode. Therefore, a slight change caused by the binding of the AZT-TP moiety was propagated to Arg70, resulting in a significant overall change in enzyme-ligand complex without deforming the '3′-OH pocket', which emulates essentially for the natural substrate (TTP) binding to the mutant RT.
Analysis of the minimized structure of reverse transcriptase-lamivudine-triphosphate complexes Among the nucleoside RT inhibitors currently used clinically, 3TC is the only one with the unnatural L-configuration. Most interestingly, 3TC and its corresponding 5-fluorinated derivative (-)-FTC, have been shown to be more potent than the D-isomers (Cammack et al., 1992; Chang & Skalski, 1992; Furman et al., 1992; Schinazi et al., 1992) . The point mutation M184V/I confer high-level resistance to 3TC (Table 1) . Met184 is located in the YMDD motif, which is highly conserved among retroviral RTs. In HIV-1 RT, this motif contains two of the three catalytic aspartates of the DNA polymerase active site. The M184V RT is more than 1000-fold less efficient in incorporating 3TC-TP into the nascent viral DNA compared with the wild-type enzyme (Table 1 ). The calculated relative binding energy (E rel ) was in good correlation with the antiviral activity of 3TC (Table 3 ). The abortive binding mode to M184V mutant obtained after minimization is particularly noteworthy. Wild type reverse transcriptase-lamivudinetriphosphate complex
The mechanistic basis for the stereochemical selectivity of 3TC and (-)-FTC is not completely understood although a number of factors may clearly come into play. The differences in potency may be a combination of factors, including uptake Chang & Skalski, 1992; Furman et al., 1992; Skalski et al., 1993) , transport (Fridland et al., 2000) , metabolic activation, incorporation Chang & Skalski, 1992; Furman et al., 1992; Skalski et al., 1993; Gray et al., 1995) , deamination (Carter, 1995; Jenuth et al., 1996) , TP binding to RT and repair (Cammack et al., 1992; Chang & Skalski, 1992; Furman et al., 1992) . A recent pre-steadystate kinetic analysis (Feng & Anderson 1999) , to determine the maximum rate of incorporation (k pol ), nucleotidebinding affinity (K d ), and efficiency of incorporation (k pol /K d ), for the D-and L-isomeric 3TC compounds as well as the corresponding 2′,3′-dideoxy and natural nucleoside triphosphate into a primer-template complex using HIV-1 RT, provided a mechanistic basis for understanding the inhibition of RT by 3TC. The maximum rate of incorporation (k pol ), followed the decreasing order of dCTP >ddCTP >(+)-BCH-189 (D-counterpart of 3TC) >3TC while the K d values determined for the DNA/RNA primer-template followed the decreasing order of 3TC ≅(+)-BCH-189 ≅ddCTP >dCTP. The corresponding efficiency of incorporation followed the decreasing order of dCTP >ddCTP >(+)-BCH-189 >3TC, which suggests that perturbations on the ribose ring of cytidine analogues (C→S) decrease the rate and efficiency of incorporation but enhance the binding affinity.
Our calculated relative binding energy indeed indicates a favourable binding of 3TC-TP to WT RT compared with its corresponding natural substrate, dCTP (Table 3) . Comparison of the minimized structure of RT/dCTP with RT/3TC-TP complexes showed that Arg72 slides down to the inhibitor binding site to form a new network of hydrogen bonds by which the oxathiolane moiety of 3TC-TP acquires further stabilization (Figure 3a) . The conformational change of Arg72 results in an inward movement of palm domain toward fingers domain to form a tighter binding mode between 3TC-TP and WT RT, which is consistent with the potent anti-HIV-1 activity of 3TC.
M184V reverse transcriptase-lamivudinetriphosphate complex
On the basis of the crystal structure of WT RT/DNA/dNTP, Huang et al. have suggested that the side chain of either a valine or an isoleucine at position 184 would interfere with 3TC-TP binding (Huang et al., 1998) . However, in the absence of structures for 3TC-resistant RTs complexed with a template-primer and 3TC-TP, the structural details of 3TC resistance have not yet been elucidated. Recently, Arnold and co-workers (Sarafianos et al., 1999) developed a model to explain the ability of 3TC-resistant mutant M184I to incorporate dNTPs but not 3TC-TP. This model was based on a comparison of the crystal structure of the WT RT/DNA complex with the structure of M184I bound to the identical oligonucleotide substrate. Even though the crystal structure is lacking the inhibitor triphosphate (3TC-TP), this model clearly shows that steric conflict between the oxathiolane ring of 3TC-TP and the side chain of β-branched amino acids (Val, Ile, Thr) at position 184 perturbs the inhibitor binding, leading to a reduced efficiency of binding of 3TC-TP. They proposed that this factor in combination with the repositioning of the template-primer Boyer et al., , 1995 Tantillo et al., 1994) could interfere with the formation of a catalytically competent closed complex between 3TC-TP and M184I/V RT. Based on our calculation, the binding of 3TC-TP to M184V RT, which shows a sharp drop of relative binding energy (E rel ) compared with that to WT RT (Table 3) , induces several changes. (1) An unminimized structure of the M184V RT/3TC-TP complex shows significant steric clash between the β-side chain of Val184 and the 3′-thio group of 3TC-TP (2.2 Å apart). During minimization, this severe conflict is somewhat relieved but still, the distance between those two groups (2.7 Å) is not long enough to prevent unfavourable binding pattern for 3TC-TP resulting from steric hindrance ( Figure 3b) ; (2) Arg72, which played a critical role in stabilizing 3TC-TP binding to WT RT, is not participating in hydrogen bonding to the sugar moiety of 3TC-TP due to significant conformational change in 3TC-TP during its escape from the steric conflict with the Val184. As Arg72 moves out of the binding site of the M184V RT/3TCTP complex, the fingers and palm domains become more separated to give a loose and abortive binding state; (3) another serious steric conflict comes into play as Met184 mutates to Val184. As Sarafianos et al. (1999) suggested, the primer residue near the mutation site, G22 (the n th residue in primer strand), is located at vicinity (0.8-1.6 Å) of Val184 resulting in a significant steric bulk. This unfavourably close contact between Val184 and primer chain results in repositioning of the template-primer duplex after minimization. A shift in the position of the primer would likely contribute to a misalignment of 3TC-TP at the transition state and a decrease in the polymerization rate or processivity.
Analysis of the mimimized structure of RT-DXGTP complex DXG and its prodrug, DAPD, have been reported to be potent inhibitors of HIV-1 (Kim et al., 1993; Siddiqui et al., 1993; Furman et al., 2001) . Antiviral assays performed in cell culture systems determined that DXG had an EC 50 value of 0.046 and 0.085 µM when evaluated against HIV-1IIIB in cord blood mononuclear cells and MT-2 cells, respectively. These values indicate that DXG is approximately equipotent to 2′,3′-dideoxy-3′-thiacytidine (3TC), but 5-to 10-fold less potent than AZT. When recombinant or clinical variants of HIV-1 were used to assess the efficacy of this purine nucleoside analogue against drugresistant HIV-1, it was observed that AZT-resistant and 3TC-resistant virus remained sensitive to DXG (Furman et al., 2001; Gu et al., 1999) . These findings have particular importance because even though AZT and 3TC are the most widely used combination therapy regimen, RT can become multidrug resistant under prolonged combination therapy (Shirasaka et al., 1995; Carpenter et al., 1997; Larder & Stammers, 1999) . The site-directed mutation study showed that three point mutations (K65R, L74V and Q151M) and one combination mutation (K65R/Q151M) showed moderate (K65R, L74V and Q151M) to high (K65R/Q151M) resistance to DXG (Mewshaw et al., 2002) . These findings were reproduced in our study with a good correlation between the relative binding energy (E rel ) and the antiviral activity, in which E rel of DXG to WT, AZT-resistant mutant (M41L,D67N,K70R,T215Y, Table  2 ) and M184V mutants (Table 3) were high enough but the binding energies significantly decreased to K65R, L74V and double mutant (K65/Q151M) ( Table 4) .
Wild type reverse transcriptase-DXG-triphosphate complex
The relative binding energies (E rel ) of DXG-TP to WT showed a favourable binding affinity toward the RT and consequently a good correlation with its biological activity (Tables 2-4). A comparison of the binding modes of WT RT to DXG-TP with its corresponding natural substrate, dGTP, showed a clear involvement of Arg72 in DXG-TP binding at the active site (Figure 4a) . In dGTP binding, Arg72 maintains its conformation, as shown in the X-ray structure of the RT*-T/P-TTP ternary complex (Huang et al., 1998) . However, when DXG-TP binds to RT (Figure  4a ), Arg72 slides down to the binding site without steric hindrance between the ε-amino and 3′-H of the sugar moiety which is lacking in DXG-TP. As a result, the protruding ε-amino group forms a new network of hydrogen bonds with its neighbouring residues, particularly with the DXGTP's dioxolane moiety and Gln151 (Figure 4a) , which results in a tight binding of the inhibitor to RT. Consequently, this inward bending of Arg72 makes the fingers and palm subdomains closer to form a tight binding structure.
The quadruple zidovudine mutant reverse transcriptase-DXG-triphosphate complex
As shown in the minimized structure of the quadruple AZT mutant (M41L, D67N, K70R, and T215Y ) RT-AZT-TP complex (Figure 2c and 2d) , the effect of these mutations did not affect the conformational change in 3′-OH binding pocket. Rather, mutation followed by conformational changes in adjacent residues and the different triphosphate binding mode may be responsible for the changes in binding energy ( Table 2 ). The favourable binding of DXGTP to the quadruple AZT mutant-RT can be explained by two factors. Mutations at 41 and 215 create small conformational changes around their positions. Therefore, several residues such as Glu40, Glu44, Lys46, Gly112 and Ser117 experience conformational changes, which propagate ultimately to the three catalytic residues Asp110, Asp185 and Asp186 through Asp110, Val111, Gly112 and Asp113 (Figure 4b ). In addition, as Asp67 mutates to Asn67, three residues Asn67, Lys219 and Asp110 form a salt bridge, which shifts Asp110 1.2 Å out of the binding site (Figure 4b ). Interestingly, this shift cannot be found in the binding mode of either AZT-TP, TTP, or dGTP to the same mutant enzyme. Therefore, the unique binding mode of DXG-TP deserves more attention. Due to the lack of a 3′-OH in DXG-TP sugar moiety, DXG-TP fails to stabilize its β-phosphate by hydrogen bonding. As a result, an adjacent residue, Lys65, moves toward the hydrogen bonding distance to the β-phosphate. However, it should be noted that in AZT-TP binding mode, the movement resides in Arg70 not in Lys65 (Figure 2c, d) , which requires further explanation. Compared with the AZT-TP binding, the interaction between Arg72 and the triphosphate moiety may be the critical factor in determining the residue, which should move. In DXG-TP binding, Arg72 rotates toward the triphosphate to form hydrogen bonds with both α-and β-phosphates. As a result, the triphosphate moiety has a more contracted conformation compared with that of AZT-TP binding, and the γ phosphate does not move out significantly. The conformational change in Lys65 propagates to Asn67 through Arg70, Thr69, and Ser68. As the conformation of Asn67 changes, the adjacent residue Lys219 pulls down to form a stable salt bridge among Asn67, Lys219 and Asp110 (Figure 4b ). The combined effect of propagation of conformational change and salt bridge formation results in conformational changes in three catalytic aspartate residues (110, 185, and 186), which improves the chelation of the two Mg atoms. The two Mg 2+ , one catalytic and the other nucleotidebinding are believed to facilitate an S N 2 nucleophilic attack by the 3′-OH of the primer terminus on the α-phosphorus of the incoming dNTP and to stabilize the negative charge in the transition state. Therefore, changes in conformation as well as binding mode of the three conserved Asp residues could contribute to an alignment of Mg atoms at the transition state and an increase in the polymerization rate or processivity. Another change followed by a salt bridge formation is the distance between fingers and palm domains. Fingers and palm domains move 1.1 Å and 0.4 Å toward each other to result in a decreased distance and therefore a tight binding state.
M184V reverse transcriptase-DXG-triphosphate complex
M184V mutation, which confers a significant resistance to 3TC, does not significantly affect DXG-TP binding. The high-level resistance of this mutant to inhibition by 3TC may be due to the unnatural L-configuration. The alignment of the triphosphate and base would cause the oxathiolane ring of 3TC to project 1.5-2.0 Å further toward residue 184 than the ribose ring of nucleotides of natural Dconfiguration. However, in view of the fact that 3TC and DXG have similar pseudo-sugar moieties (oxathiolane and dioxolane, respectively) and 2′,3′-dideoxy nucleosides with natural D-configuration such as zalcitabine (ddC) and didanosine (ddI) show some low-level cross-resistance to M184V mutant, it is not clear why DXG still maintains its anti-HIV-1 activity against M184V mutant strains. Our calculated relative binding energy (E rel ) suggests (Table 3) that DXG-TP can maintain its favourable binding affinity toward M184V mutant RT but with reduced degree, which can be correlated with 2.1-fold resistance. The minimized structure (Figure 4c) shows that there is enough distance (3.8 Å) between Val184 and DXGTP to avoid unfavourable steric conflict, and the distances between palm and fingers domains are exactly the same in DXG-TP and dGTP binding. This favourable binding to DXG-TP compared to dGTP comes from the T/P repositioning followed by a change in the puckering of the dioxolane sugar ring. As methionine mutates to valine (M184V), the adjacent nucleotide in the primer chain (G22) experiences greater steric bulk (1.6 Å) with the mutated residue. Therefore, minimization shifts the entire template-primer about 0.4 Å out of the binding site, and this change propagates to the adjacent DXG-TP to make a 0.7 Å movement of the sugar moiety down to the 3′-OH pocket ( Figure 4c ). The accompanying conformational change in the sugar moiety, from 3′-endo to 3′-exo, in combination with the reduced distance (2.2 Å) between 3′-O and backbone-NH group of Tyr115, enables a stabilizing hydrogen bonding between DXG-TP and 3′-OH pocket ( Figure  4c ). Overall, the M184V mutation does not sterically hinder DXG-TP binding, but enables a more stable binding of DXGTP through a new hydrogen bond between the 3′-oxygen of sugar moiety and the backbone-NH group of Tyr115.
K65R RT-DXGTP complex
Several ddN resistance mutations arise in the flexible β3-β4 loop situated in the fingers domain of the p66 subunit of RT (Larder & Stammers, 1999) . Five residues, that form part of this loop (Ile63, Lys64, Lys65, Tyr71 and Arg72), are conserved in all retroviral RTs (Moyle, 1995) and among those, two fingers residues make important contacts with the dNTP substrate. The ε-amino group of Lys65 and the guanidinium group of Arg72 make salt bridges with the γ-and α-phosphates of the bound dNTP substrate, respectively. These interactions help positioning the dNTP for base-pairing with the complementary template residue as well as for catalysis of phosphodiester bond formation with the 3′-OH of the primer terminal nucleotide. While the available structural data have provided considerable information on the structure of RT as well as the relevant amino acid residues critical for catalysis, it has not provided the molecular mechanism by which mutations on RT influence the dNTP binding, thereby the anti-HIV potency. Our calculation indicates that DXG-TP shows a large decrease in its relative binding energy (E rel ) to the mutant enzyme, K65R RT, compared with that of WT RT (Table 4) , which is in good correlation with the increased resistance obtained with the K65R mutant. This decrease in binding energy can be explained by the outward rotation of Arg72 from the binding site in DXG-TP binding mode (Figure 4d ). This conformational change, initiated by the movement of Arg65 toward the binding site, results in the loss of hydrogen bonds between Arg72 and DXG-TP dioxolane moiety and Gln151 (Figure 4d ). The movement of Arg65 toward the binding site in DXG-TP binding mode, as discussed above, can be explained by the extensive stabilization of triphosphate of DXTP by ε-amino group of Arg65 because DXG-TP is lacking the stabilizing interaction between 3′-OH of sugar moiety and β-phosphate. Therefore, for the sake of stabilization of triphosphate moiety of DXGTP, Arg65 slides into the binding site, and, as a result, the nearby Arg72 is pushed away from the binding site. As a consequence, the fingers and palm domains are departing from each other to give a less productive transition state, resulting in the DXG-TP resistance.
L74V mutant reverse transcriptase-DXGtriphosphate complex
In the structure of RT-DNA-dNTP (Huang et al., 1998) , Leu74 is not in a position to directly affect dNTP binding. However, it does interact with the template nucleotide that is base paired to the incoming dNTP and is also proximal to Gln151, which is a key residue in the dNTP-binding pocket. The L74V mutation has been thought to reduce sensitivity to ddI and ddC by altering template position and/or by affecting the orientation of Arg72 and Gln151 sidechains (St Clair et al., 1991; . Leu74 upholds the template nucleotide by hydrophobic interactions so that the template nucleotide could be base paired with the incoming dNTP. Therefore, the mutation of this residue from leucine to valine results in the misalignment of the template residue for base pairing and a significant conformational change in adjacent residues such as Gln151 and Arg72 (Figure 4e) . In DXGTP binding, the combined effect of the misalignment of base pairing and the conformational change in Arg72 results in the downward shift of the dioxolane ring and the conformational change in the triphosphate moiety, which is in good agreement with the decreased binding affinity (Table 4) . However, in dGTP binding, Arg72 and the triphosphate moiety can maintain their conformation because the 3′-OH group in 2′-deoxyribose ring is involved in the stabilization of the β-phosphate group. As a result, the TP moiety of DXG-TP adopts a new conformation, which hampers the formation of optimal geometry for S N 2 type polymerization reaction: the distance between the nucleophile (3′-OH at the end of primer strand) and the reaction center (phosphorous atom at a phosphate moiety) is lengthened (3.66 Å, in WT the distance is 3.42 Å) and the angle among the nucleophile, reaction center and the leaving group (β and γ phosphates) (160.4°) deviates from that of optimal value (177.0°in WT) (Table 5 ).
Double mutant (K65R/Q151M) reverse transcriptase-DXG-triphosphate complex
In the crystal structure of the ternary complex, Gln151 interacts with residues that either directly interact with dNTP (for example, Arg72, which hydrogen bonds with dNTP) or affect the position of important structural elements (for example, the main chain carbonyl oxygen of residue 73 is hydrogen-bonded to Gln151, bridging the palm and fingers subdomains) (Huang et al., 1998) . The Q151M mutation might therefore engender multidrug resistance to AZT, stavudine (d4T) and ddC/ddI by inducing both direct and indirect changes at the dNTP-binding pocket (Table 1) (Shirasaka et al., 1995; Iversen et al., 1996) . A site-directed mutagenesis study found that a combination mutation of K65R and Q151M was fully resistant to DXG-TP and this mutant exhibits a significant decrease in antiviral activity of DXG-TP (Table 4 ). The decreased relative binding energy (E rel , Table 4 ) and the minimized RT-DXG-TP structure shows two important features. The bulky Met151 pushes neighbouring Arg65 away from the binding site (Figure 4f ) . In dGTP binding, the pushed Arg65 also rotates itself in order to prevent another steric hindrance with the adjacent residue Lys70. However, in DXG-TP binding, Arg65 is heavily involved in the stabilization of β-phosphate and can neither move out nor rotate to prevent the unfavourable steric hindrance with Met151 and Lys70, which results in a high-energy binding state (Figure 4f ). In addition to that, as with the L74V mutation, the geometry for S N 2 type polymerization reaction is significantly deformed as a result of conformational change in both Arg65 and the triphosphate moiety in DXG-TP: the nucleophile and the reaction centre are separated by 4.40 Å, and the angle around the reaction centre (158.8°) deviates significantly from that of the WT (Table  5) . Therefore, the incorporation of DXG-TP into the growing DNA chain in K65R/Q151M mutant enzyme can be expected to be more difficult than in any other mutant enzymes studied.
Discussion
There have been numerous efforts to understand the molecular mechanism of resistance to nucleoside reverse transcriptase inhibitors conferred by mutations in HIV-1 RT. In the absence of the structural information of the mutant RT, several groups reported molecular modeling approaches to support their results. However, there has not been a comprehensive approach toward this goal. Even though the computational methods used in this study is far from ideal and the appropriate solvent effect was not taken into consideration, by constructing mutation sites by molecular modeling and comparing the relative binding energies (E rel ) of the NRTI triphosphates to RT, we determined that the antiviral activity of the nucleoside RT inhibitors can be influenced by the binding affinity of their triphosphates to RT.
The interactions between the NRTI triphosphates and adjacent amino acid residues (Lys65, Lys70, Arg72, Tyr115 and/or Gln151) played important roles in stabilizing the enzyme-inhibitor complex. Particularly, Arg72 was found to stabilize the dioxolane and oxathiolane sugar moiety through hydrogen bonding, which was also responsible for favourable binding affinity of DXG-TP to AZT-and 3TC-resistant mutants. The binding interactions of NRTI triphosphates (AZT-TP, 3TC-TP and DXG-TP) with WT RT showed that NRTI triphosphates can bind to the enzyme more tightly than the corresponding dNTPs because of either participation of Arg72 in stabilizing dioxolane (DXG-TP) or oxathiolane (3TC-TP) ring, or formation of hydrogen bonding of azido group with the 3′-OH pocket (Tyr115 and Phe116) (AZTTP). In addition, our study provided a possible molecular mechanism for the resistance of RT toward antiviral nucleoside inhibitors. The rapid development of the significant 3TC-resistance by M184V RT could be explained by the steric hindrance between the Val184 and the unnatural L-oxathiolane moiety of 3TC, and this may be the general mechanism of the cross-resistance of M184V RT to many L-nucleoside RT inhibitors. AZT-TP fails to stabilize its β-phosphate moiety due to the lack of 3′-hydroxy group, which allows an extended conformation of its triphosphate. The mutated residue, Arg70, moves out of the binding site interacting with the γ-phosphate, which results in a loose AZT-TPmutant RT (M41L/D67N/K70R/T215Y ) complex. The minimized structures of DXG-TP-mutant RTs gave us reasonable explanation for antiviral activity of DAPD, a prodrug of DXG, against the AZT-and 3TC-resistant mutants, where D-dioxolane sugar moiety of DXGTP provided interesting advantages The natural D-configuration did not experience any significant steric hindrance with the Val184 in M184V RT, and the 3′-oxygen allowed a stabilizing hydrogen bonding with the -NH backbone of Tyr115. In addition, the 3′-oxygen instead of 3′-CH 2 allowed the approach of Arg72 to stabilize the dioxolane ring moiety by hydrogen bonding. In AZT-resistant mutant RT, dioxolane ring induced the formation of a salt bridge among Asn67, Lys219 and Asp110 to result in a stable complex. Interestingly, the conformational changes in the amino acid residues, which are in close contact with the NRTI triphosphates always affected the changes in the tertiary structures of enzyme-inhibitor complexes through either closing or opening the gap between the fingers and palm domains. Therefore, enzyme-inhibitor complexes with good binding affinity showed tight binding modes by closing the gap between the two domains, whereas weak inhibitors gave open and loose complexes.
Based on this preliminary information about the molecular mechanism conferred by mutations at HIV-1 RT, an exhaustive and a more computationally expensive treatment of this system is underway, including the solvent (water) molecules and using molecular dynamics simulations.
